Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The amyloid cascade hypothesis: an updated critical review
Kasper P. Kepp, Nikolaos K. Robakis, Poul Flemming Høilund‐Carlsen, et al.
Brain (2023) Vol. 146, Iss. 10, pp. 3969-3990
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 54
Cellular and pathological functions of tau
C Bravo, Sarah Naguib, Li Gan
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 11, pp. 845-864
Closed Access | Times Cited: 21
Familial Alzheimer mutations stabilize synaptotoxic γ-secretase-substrate complexes
Sujan Devkota, Rui Zhou, Vaishnavi Divya Nagarajan, et al.
Cell Reports (2024) Vol. 43, Iss. 2, pp. 113761-113761
Open Access | Times Cited: 15
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Ernesto Fedele
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14499-14499
Open Access | Times Cited: 31
The Role of TNF-α in Alzheimer’s Disease: A Narrative Review
Domenico Plantone, Matteo Pardini, Delia Righi, et al.
Cells (2023) Vol. 13, Iss. 1, pp. 54-54
Open Access | Times Cited: 20
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Faizan Ahmad, Anik Karan, Rashi Sharma, et al.
Ageing Research Reviews (2024) Vol. 95, pp. 102229-102229
Closed Access | Times Cited: 11
Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Poul Flemming Høilund‐Carlsen, Abass Alavi, Rudolph J. Castellani, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3892-3892
Open Access | Times Cited: 11
Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History
Félix Bermejo‐Pareja, Teodoro del Ser
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 536-536
Open Access | Times Cited: 9
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit
Poul F. Høilund‐Carlsen, Abass Alavi, Jorge R. Barrio, et al.
Ageing Research Reviews (2024) Vol. 99, pp. 102348-102348
Closed Access | Times Cited: 8
Possible Role of Fibrinaloid Microclots in Postural Orthostatic Tachycardia Syndrome (POTS): Focus on Long COVID
Douglas B. Kell, Asad Khan, Binita Kane, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 2, pp. 170-170
Open Access | Times Cited: 6
Mitochondrial Transportation, Transplantation, and Subsequent Immune Response in Alzheimer’s Disease: An Update
Pegah Javadpour, Fatemeh Abbaszadeh, Abolhassan Ahmadiani, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 9, pp. 7151-7167
Closed Access | Times Cited: 6
More failure with solanezumab – this time in preclinical Alzheimer’s disease
Sheila A Doggrell
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 119-123
Closed Access | Times Cited: 6
Physical Exercise Counteracts Aging-Associated White Matter Demyelination Causing Cognitive Decline
Tanya Butt, Makoto Tobiume, Diane B. Ré, et al.
Aging and Disease (2024) Vol. 15, Iss. 5, pp. 2136-2136
Open Access | Times Cited: 6
Multi-omics analyses of early-onset familial Alzheimer's disease and Sanfilippo syndrome zebrafish models reveal commonalities in disease mechanisms
Karissa Barthelson, Rachael A. Protzman, Marten F. Snel, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 3, pp. 167651-167651
Closed Access
Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy
Emma Ortiz, Pedro Montes, Citlali Ekaterina Rodríguez-Pérez, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 128-128
Open Access
Lipid-protecting disulfide bridges are the missing molecular link between ApoE4 and sporadic Alzheimers disease in humans
Christopher E. Ramsden, Roy G. Cutler, Xiufeng Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production
Parnian Arafi, Sujan Devkota, Emily L. Williams, et al.
(2025)
Open Access
Communicating scientific evidence: drugs for Alzheimer's disease as a case study
Kasper P. Kepp, Poul F. Høilund‐Carlsen, Ioana A. Cristea, et al.
Current Medical Research and Opinion (2025), pp. 1-15
Closed Access
Bis(7)-harmine derivatives as potential multi-target anti-Alzheimer agents
Hongtao Du, Fang Ma, Yuanyuan Cao, et al.
Frontiers in Chemistry (2025) Vol. 13
Open Access
Predicting conversion in cognitively normal and mild cognitive impairment individuals with machine learning: Is the CSF status still relevant?
Mirella Russo, Davide Nardini, Sara Melchiorre, et al.
Alzheimer s & Dementia (2025)
Open Access
Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer’s disease
Francesco Panza, Vittorio Dibello, Rodolfo Sardone, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production
Parnian Arafi, Sujan Devkota, Emily L. Williams, et al.
eLife (2025) Vol. 13
Open Access
Once upon a time, the Amyloid Cascade Hypothesis
Alberto Granzotto, Stefano L. Sensi
Ageing Research Reviews (2023) Vol. 93, pp. 102161-102161
Open Access | Times Cited: 16
Monoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials
Ian Scott
Age and Ageing (2024) Vol. 53, Iss. 2
Closed Access | Times Cited: 5
Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice
Luisa Agnello, Caterina Maria Gambino, Anna Maria Ciaccio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4323-4323
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top